Quote:

---

Gilead paid $21B for a single indication, and early data suggests LL offers much better results for that indication.

---

To this argument, BP could respond: “MAY offer.” Gilead paid $21B for the drug upon its FDA approval:

Quote:

---

The FDA approved Trodelvy based on the results of a clinical trial of 108 patients with metastatic triple-negative breast cancer who had received at least two prior treatments for metastatic disease. The efficacy of Trodelvy was based on the overall response rate (ORR) – which reflects the percentage of patients that had a certain amount of tumor shrinkage. The ORR was 33.3%, with a median duration of response of 7.7 months. Of the patients with a response to Trodelvy, 55.6% maintained their response for 6 or more months and 16.7% maintained their response for 12 or more months.

---